1. |
Yancik R, Ries LA. Aging and cancer in America. Demographic and epidemiologic perspectives[J]. Hematol Oncol Clin North Am, 2000, 14(1):17-23.
|
2. |
Hickey M, Peate M, Saunders CM, et al. Breast cancer in young women and its impact on reproductive function[J]. Hum Reprod Update, 2009, 15(3):323-339.
|
3. |
中国广播网. 中国第六次人口普查[EB/OL]. http://native. cnr. cn/list/201208/t20120810_510541842. html.
|
4. |
Althuis MD, Dozier JM, Anderson WF, et al. Global trends inbreast cancer incidence and mortality 1973-1997[J]. Int J Epid-emiol, 2005, 34(2):405-412.
|
5. |
NCCN. Clinical Practice Guidelines in Oncology (NCCN Guidelines)-Breast Cancer[EB/OL]. http://www.nccn. com/cancer-guidelines. html.
|
6. |
Brunello A, Basso U, Pogliani C, et al. Adjuvant chemotherapy for elderly patients (>or=70 years) with early high-risk breast cancer:a retrospective analysis of 260 patients[J]. Ann Oncol, 2005, 16(8):1276-1282.
|
7. |
应红艳, 白春梅, 管梅, 等. 老年乳腺癌患者的临床病理特点及治疗影响因素[J]. 中国医学科学院学报, 2010, 32(4):398-402.
|
8. |
Holmes CE, Muss HB. Diagnosis and treatment of breast cancer in the elderly[J]. CA Cancer J Clin, 2003, 53(4):227-244.
|
9. |
Office for National Statistics 2010-based period expectation of life, 1981-2060. United Kingdom:Principal Projection[EB/OL].http://www. ons. gov. uk/ons/publications/re-referencetables. html?edition=tcm%3A77-227587.
|
10. |
新年龄分段[EB/OL]. http://baike. baidu. com/view/10593790. htm.
|
11. |
Muss HB, Berry DA, Cirrincione CT, et al. Adjuvant chemotherapy in older women with early-stage breast cancer[J]. N Engl J Med, 2009, 360(20):2055-2065.
|
12. |
Muss HB, Woolf S, Berry D, et al. Adjuvant chemotherapy in older and younger women with lymph node-positive breast cancer[J]. JAMA, 2005, 293(9):1073-1081.
|
13. |
Singh R, Hellman S, Heimann R. The natural history of breast carcinoma in the elderly:implications for screening and treatment[J]. Cancer, 2004, 100(9):1807-1813.
|
14. |
Jung SP, Lee JE, Lee SK, et al. Adjuvant chemotherapy and survival of elderly korean patients with breast carcinoma[J]. J Breast Cancer, 2012, 15(3):296-305.
|
15. |
Fargeot P, Bonneterre J, Roché H, et al. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients:6-year follow-up results of the French adjuvant study group 08 trial[J]. J Clin Oncol, 2004, 22(23):4622-4630.
|
16. |
Biganzoli L, Wildiers H, Oakman C, et al. Management of elderlypatients with breast cancer:updated recommendations of the Intern-ational Society of Geriatric Oncology (SIOG) and European Societyof Breast Cancer Specialists (EUSOMA)[J]. Lancet Oncol, 2012, 13(4):148-160.
|
17. |
Early Breast Cancer Trialists’ Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival:an overview of the randomised trials[J]. Lancet, 2005, 365(9472):1687-1717.
|
18. |
Giordano SH, Duan Z, Kuo YF, et al. Use and outcomes of adjuvant chemotherapy in older women with breast cancer[J]. J Clin Oncol, 2006, 24(18):2750-2756.
|
19. |
Elkin EB, Hurria A, Mitra N, et al. Adjuvant chemotherapy and survival in older women with hormone receptor-negative breast cancer:assessing outcome in a population-based, observational cohort[J]. J Clin Oncol, 2006, 24(18):2757-2764.
|
20. |
Debled M, Bellera C, Donamaria C, et al. Chemotherapy treatment for older women with metastatic breast cancer:what is the evidence?[J]. Cancer Treat Rev, 2011, 37(8):590-598.
|
21. |
Jones S, Holmes FA, O’Shaughnessy J, et al. Docetaxel withcyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide:7-year follow-up of US Oncology Research Trial 9735[J]. J Clin Oncol, 2009,.
|
22. |
Ladoire S, Rambach L, Quipourt V, et al. Feasibility and safety of weekly sequential epirubicin-paclitaxel as adjuvant treatment for operable breast cancer patients older than 70 years[J]. Clin Breast Cancer, 2011, 11(4):235-240.
|
23. |
(2):130-137.
|
24. |
Crivellari D, Gray KP, Dellapasqua S, et al. Adjuvant pegylatedliposomal doxorubicin for older women with endocrine nonrespo-nsive breast cancer who are not suitable for a “standard chemotherapy regimen”:the CASA randomized trial[J]. Breast, 2013,.
|
25. |
Dellapasqua S, Colleoni M, Castiglione M, et al. New criteria for selecting elderly patients for breast cancer adjuvant treatment studies[J]. Oncologist, 2007, 12(8):952-959.
|
26. |
Leonard R, Ballinger R, Cameron D, et al. Adjuvant chemotherapy in older women (ACTION) study-what did we learn from the pilot phase?[J]. Br J Cancer, 2011, 105(9):1260-1266.
|
27. |
(8):1177-1183.
|